# SS-31 (Elamipretide): Cardiolipin Targeting, Mitochondrial Electron Transport Chain Optimization, and Reconstitution Principles

## Key Takeaways

- **Primary Biochemical Mechanism:** SS-31 (D-Arg-Dmt-Lys-Phe-NH2) is a synthetic, water-soluble, cell-permeable tetrapeptide that selectively binds the inner mitochondrial membrane phospholipid cardiolipin via electrostatic interaction between its N-terminal D-arginine cationic charge and cardiolipin's anionic phosphate headgroups, combined with hydrophobic intercalation of the 2',6'-dimethyltyrosine (Dmt) aromatic side chain into the lipid acyl core, thereby stabilizing cristae curvature, optimizing supercomplex assembly of the electron transport chain (ETC), and reducing electron leak and reactive oxygen species (ROS) generation.
- **Receptor Selectivity and Signaling:** SS-31 does not engage classical cell-surface G protein-coupled or kinase-linked receptors; instead, it functions as an interfacial membrane-targeting pharmacophore with organellar selectivity governed by the proton motive force, which concentrates the aromatic cationic peptide at the negatively charged mitochondrial matrix face, where it restores cytochrome c tethering to cardiolipin, preserves Complex I/III/IV supercomplex stoichiometry, and indirectly sustains ATP synthase (Complex V) proton-channeling efficiency without direct enzymatic activation.
- **Pharmacokinetics and Structural Stability:** The alternating D-Arg / Dmt / L-Lys / L-Phe-NH2 sequence, including the C-terminal amide cap, confers resistance to endogenous peptidase and aminopeptidase hydrolysis, yielding an estimated plasma half-life supportive of subcutaneous administration, low cytochrome P450 interaction liability due to its non-redundant tetrapeptide mass (~639.8 g/mol free base; ~855 g/mol as the trifluoroacetate clinical salt), and preferential mitochondrial accumulation over cytosolic distribution driven by membrane potential-dependent partitioning.
- **Volumetric Reconstitution Dynamics:** Reconstitution is governed by the standard molarity equation M = m / (MW × V), requiring accurate gravimetric input of the peptide vial mass (accounting for salt form and counterion contribution when using the 855.04 g/mol clinical formulation versus the 639.8 g/mol free base), sterile bacteriostatic water or aqueous diluent as the solvent variable, with the final working concentration directly determined by diluent volume; typical laboratory workflows generate stock concentrations in the 1 to 10 mg/mL range, with downstream dilution mathematics validated through the Peptide Reconstitution Calculator to ensure theoretical molar accuracy prior to in vitro experimental application.
- **Clinical-Translational Rationale:** Cardiolipin stabilization by SS-31 directly addresses mitochondrial bioenergetic failure phenotypes documented in Barth syndrome, acute kidney injury, and heart failure, positioning the tetrapeptide as a structure-based membrane integrity restorative agent rather than a conventional receptor agonist or antagonist, with therapeutic hypothesis generation and mechanistic interpretation remaining dependent on controlled in vitro and preclinical laboratory investigation.

> **Academic Research & Educational Disclaimer:** This scientific monograph is published exclusively for academic research, molecular biology education, laboratory investigation, and informational reference. Unapproved synthetic peptides discussed herein are intended strictly for in vitro and controlled preclinical laboratory research by qualified scientific investigators and are not intended for human consumption, direct medical self-administration, diagnostic application, or therapeutic use without direct medical supervision and valid clinical authorization. All concentration and volumetric calculations derived from the [Peptide Reconstitution Calculator](/tools/peptide-calculator) represent theoretical laboratory mathematical models based on molarity, vial mass, and diluent volume, and do not constitute clinical prescribing advice or human dosing recommendations.

## Discovery, Natural Biosynthesis, and Structural Architecture of SS-31 (Elamipretide)

### Historical Discovery and Rational Design of a Cardiolipin-Targeting Pharmacophore

The development of SS-31, generically designated elamipretide, represents a paradigm shift from traditional enzyme inhibition toward the stabilization of organellar membrane microdomains. Originally conceptualized by Hazel H. Szeto and Peter W. Schiller through a structure-activity relationship program focused on the scavenging of mitochondrial reactive oxygen species, the compound emerged from a library of synthetic, water-soluble tetrapeptides engineered with alternating aromatic and basic residues [4]. Early lead optimization was guided by the hypothesis that the proton motive force across the inner mitochondrial membrane could be leveraged to concentrate aromatic cation pharmacophores at the mitochondrial matrix surface. The critical breakthrough was the recognition that the compound's interaction with the lipid phase, specifically cardiolipin, was the operative mechanism, thereby refining the molecular design to optimize interfacial partitioning rather than mere electrochemical accumulation [4]. This shift in mechanistic rationale laid the groundwork for the clinical evaluation of elamipretide in pathologies characterized by mitochondrial bioenergetic failure, including Barth syndrome and acute kidney injury [1, 2].

### Primary Structural Architecture and Sequence-Dependent Biophysics

Elamipretide is formally defined as a synthetic, cell-permeable, mitochondrially-targeted tetrapeptide with the canonical sequence D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2, frequently abbreviated as Dmt-D-Arg-Phe-Lys-NH2 when utilizing standard amino acid nomenclature, though the clinical stereochemistry is strictly defined as D-Arg-(2,6-dimethyl)-Tyr-Lys-Phe-NH2 [4]. The molecular formula is C32H53N9O5, yielding a monoisotopic mass of 643.4169 Da and a molecular weight of approximately 639.8 g/mol for the free base, with a reported molecular weight of 855.04 g/mol as the clinical formulation incorporates a trifluoroacetate salt and includes associated counterions [4]. The structural design is non-redundant, relying on the cooperative contributions of four distinct chemical moieties. The N-terminal D-arginine residue confers a permanent cationic charge at physiological pH, establishing a high affinity for anionic biological membranes. Adjacent to this is the unnatural 2',6'-dimethyltyrosine, which provides a bulky, lipophilic aromatic anchor critical for intercalation into the hydrophobic fatty acyl core of the phospholipid bilayer. The C-terminal dipeptide segment, comprising Lys-Phe, is capped by an amide modification that confers resistance to aminopeptidase and carboxypeptidase-mediated hydrolysis, enhancing the in vivo plasma half-life. The 3+ net charge at physiological pH is a fundamental determinant of the molecule's electrostatic steering toward the polarized inner mitochondrial membrane [4].

### Membrane Partitioning Kinetics and Vectorial Accumulation

The mechanism of mitochondrial uptake fundamentally diverges from classic carrier-mediated transport, relying instead on the Nernst equation and the electrochemical gradient maintained by the electron transport chain. SS-31 carries a net charge of +3 at physiological pH, which results in an approximately 1000- to 5000-fold concentration gradient across the inner mitochondrial membrane, given its potential of roughly -150 to -180 mV [4]. Experimental evidence derived from fluorescently labeled analogs and radio-tracer accumulation studies has consistently demonstrated that the uptake of SS-31 is rapid, reaching steady-state matrix loading within 5 to 15 minutes, and is reversibly inhibited by the proton ionophore carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), confirming the dependence on mitochondrial polarization [4]. While the initial accumulation is driven by the membrane potential, the subsequent binding to cardiolipin is largely potential-independent, indicating that the primary pharmacological site of action is the lipid-protein interface of the cristae rather than the matrix lumen [4].

### Cardiolipin Binding Stoichiometry and Interfacial Adsorption

The therapeutic and biochemical signature of SS-31 is inextricably linked to its selective, high-affinity binding to cardiolipin, a unique tetra-acyl phospholipid localized almost exclusively to the inner mitochondrial membrane. Binding studies utilizing surface plasmon resonance and equilibrium dialysis have established that SS-31 binds cardiolipin via an electrostatic and hydrophobic adsorption mechanism with reported affinity constants in the low micromolar range [4]. The critical determinant of binding is the 2',6'-dimethyltyrosine residue. Solid-state nuclear magnetic resonance and molecular dynamics simulations have demonstrated that the dimethylated tyrosine ring intercalates parallel to the lipid acyl chains, inserting itself into the glycerol backbone region of cardiolipin [4]. The cationic D-arginine and lysine residues form salt bridges with the negatively charged phosphate headgroups of the cardiolipin molecule. This dual-interaction model stabilizes the lamellar phase of cardiolipin, preventing the transition to the inverted hexagonal phase that typically accompanies oxidative damage. Notably, SS-31 demonstrates a strict selectivity for cardiolipin over other abundant phospholipids, such as phosphatidylcholine and phosphatidylethanolamine, as well as over the precursor phosphatidylglycerol, reflecting a precise molecular complementarity that is essential for its protective profile [4].

### Natural Biosynthesis Context and Synthetic Manufacturing Constraints

It is critical to differentiate the synthetic chemistry of elamipretide from any proposed natural ribosomal or non-ribosomal biosynthetic pathway; SS-31 is exclusively a product of solid-phase peptide synthesis, incorporating the non-proteinogenic residue 2',6'-dimethyltyrosine and a D-amino acid, features that necessitate stepwise chemical coupling rather than biological expression [4]. The synthetic route employs standard Fmoc chemistry, with the C-terminal phenylalanine loaded onto a Rink amide resin to ensure the C-terminal amidation. Following sequence elongation, the peptide is cleaved from the resin using a trifluoroacetic acid-scavenger cocktail, which simultaneously removes the side-chain protecting groups. This reliance on synthetic organic chemistry means that clinical-grade elamipretide is produced as a heterogeneous mixture of stereoisomers only at the precise residues required for activity, with strict quality control ensuring the absence of epimerization at the L-lysine and L-phenylalanine positions [4]. In vivo, the molecule does not undergo significant metabolic degradation; its primary route of clearance is renal excretion of the intact parent compound, resulting in a plasma half-life of approximately 2 to 4 hours in human subjects, which supports a once-daily subcutaneous dosing regimen in clinical trials [4].

### Reconstitution Principles and Handling Protocols

For laboratory and experimental applications, SS-31 trifluoroacetate salt is typically supplied as a lyophilized white to off-white powder. The reconstitution protocol is a critical variable for downstream experimental reproducibility, particularly in cell-based and isolated mitochondria assays. The recommended initial solvent is sterile, nuclease-free deionized water or, for stock concentrations exceeding 5 mM, a maximum of 10% to 20% dimethyl sulfoxide or 100% ethanol may be required to ensure complete solubilization [4]. The peptide is highly soluble in aqueous media at physiological pH due to its cationic character. Vortexing should be avoided to prevent degradation of the peptide, and solutions should be aliquoted to minimize freeze-thaw cycles. For in vivo administration in preclinical models, SS-31 is most commonly formulated in normal saline and administered via subcutaneous, intraperitoneal, or intravenous injection, with dose ranges typically spanning 0.5 to 10 mg/kg depending on the disease model, such as the spinal cord injury paradigms reported in recent literature [3].

### Relationship to the Mitochondrial Respirasome and Clinical Relevance

The functional consequences of cardiolipin stabilization are directly observable in the preservation of the mitochondrial respirasome, specifically the supercomplexes formed between Complex I (NADH:ubiquinone oxidoreductase), Complex III (cytochrome bc1), and Complex IV (cytochrome c oxidase) [5]. By maintaining cardiolipin in its functional, tetrameric conformation, SS-31 preserves the lipid scaffold required for the optimal interaction of these electron transport chain components, thereby optimizing electron flux and minimizing electron leak. This mechanism was identified as a key target in cadmium-induced cardiolipin rigidification, where SS-31 was shown to prevent the disruption of respirasome assembly and redox balance [5]. The clinical translation of this biochemical stabilization is being actively pursued in Barth syndrome, where a genetic defect in the TAZ gene leads to a deficiency of mature cardiolipin, and SS-31 has demonstrated efficacy in improving cardiac and skeletal muscle function in case reports and clinical trials [2]. Furthermore, its role in the treatment of acute kidney injury is being mechanistically validated, as SS-31 preserves mitochondrial bioenergetics in renal tubular cells subjected to ischemic or nephrotoxic insults [1].

## Receptor Pharmacology, Binding Affinity Kinetics, and Intracellular Second Messenger Cascades

### Receptor Pharmacology Paradigm of SS-31 (Elamipretide)

The pharmacological identity of SS-31 (elamipretide), a synthetic, water-soluble, aromatic-cationic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2; molecular weight 639.8 Da), fundamentally diverges from classical receptor-ligand interactions. Unlike G protein-coupled receptor (GPCR) or enzyme-targeted ligands, SS-31 does not exhibit measurable binding affinity (Ki, Kd) toward traditional cell-surface receptors, nuclear hormone receptors, or cytosolic signaling proteins. Instead, its pharmacodynamic profile is governed by **electrostatic and hydrophobic interactions with mitochondrial anionic phospholipids**, principally cardiolipin (CL), a unique dimeric diphosphatidylglycerol lipid exclusive to the inner mitochondrial membrane (IMM) [4]. The cationic motif, comprising a D-arginine residue and a dimethyltyrosine residue, facilitates a rapid, concentration-dependent accumulation within mitochondria driven by the organelle's highly negative transmembrane potential (approximately -150 to -180 mV). Once localized, the peptide intercalates into the hydrophobic domain of cardiolipin via its aromatic dimethyltyrosine and phenylalanine residues, yielding a non-covalent, reversible stabilization of cardiolipin microdomains [4].

### Binding Affinity Kinetics and Lipid Interaction Dynamics

Although SS-31 lacks a singular proteinaceous receptor, its binding interactions with cardiolipin can be quantified using surface plasmon resonance, isothermal titration calorimetry, and mitochondrial membrane partition assays. Reported binding affinities in model membrane systems demonstrate dissociation constants (Kd) ranging from approximately 50 nM to 200 nM for cardiolipin-enriched liposomes, depending on the acyl-chain composition of the lipid substrate. The interaction is heavily dependent on the **tetralinoleoyl-cardiolipin (L4-CL)** content, the predominant physiological species in healthy mammalian mitochondria. SS-31 demonstrates a marked selectivity for L4-CL over cardiolipin species with oxidized or short-chain acyl groups, a feature that is mechanistically relevant under conditions of oxidative stress [4]. Because SS-31 binds a lipid rather than a receptor, classical occupancy-based efficacy metrics (EC50) are replaced by **lipid-partition coefficients and membrane residence times**, which are typically in the order of several minutes, as measured by fluorescence recovery after photobleaching (FRAP) studies in supported lipid bilayers.

### Cardiolipin-Cytochrome c Anchoring and Electron Transport Chain (ETC) Reorganization

The structural integrity of cardiolipin is indispensable for the proper assembly and stability of **Complex III (ubiquinol-cytochrome c reductase) and Complex IV (cytochrome c oxidase)** supercomplexes, collectively termed the respirasome. Cardiolipin functions as a "glue" that tethers cytochrome c to the outer leaflet of the IMM via both electrostatic and hydrophobic interactions. Under oxidative stress, cardiolipin undergoes peroxidation catalyzed by cardiolipin-specific peroxidase activity of cytochrome c, which leads to its dissociation and the subsequent release of cytochrome c into the intermembrane space, a hallmark event in the intrinsic apoptotic cascade. SS-31 competitively displaces cytochrome c from peroxidized cardiolipin, thereby re-establishing the native anchorage and optimizing electron flux between Complexes III and IV [3, 4]. Studies in Barth syndrome patient-derived lymphoblasts, which harbor mutations in the *TAFAZZIN* gene and exhibit abnormal monolysocardiolipin accumulation, demonstrate that SS-31 restores mitochondrial membrane potential (ΔΨm) and increases ATP synthesis rates by approximately 30-50% in vitro, without directly donating electrons to the ETC [2].

### Second Messenger Cascade: Cytoprotective Kinase Pathways

Although SS-31 does not engage classical GPCR-coupled second messenger pathways (Gs/cAMP/PKA, Gq/IP3/DAG, or arrestin), it modulates downstream kinase signaling cascades indirectly through **mitochondrial retrograde communication**. By preserving mitochondrial reactive oxygen species (mtROS) homeostasis and limiting cardiolipin oxidation, SS-31 attenuates the activation of the nod-like receptor protein 3 (NLRP3) inflammasome and downstream caspase-1 maturation, a process linked to the release of mitochondrial damage-associated molecular patterns (mtDAMPs), including oxidized mitochondrial DNA and cardiolipin itself [1]. Furthermore, SS-31 treatment is associated with the upregulation of the **PI3K/Akt survival axis** and the suppression of stress-activated JNK and p38 MAPK phosphorylation in renal tubular epithelial cells exposed to ischemic injury. In rodent models of cisplatin-induced acute kidney injury (AKI), SS-31 (10 mg/kg/day, subcutaneous) reduced tubular apoptosis by approximately 60%, a finding correlated with decreased Bax/Bcl-2 ratios and preserved mitochondrial cristae architecture on electron microscopy [1].

### Mitochondrial Permeability Transition Pore (mPTP) Modulation

A significant component of the cytoprotective signaling elicited by SS-31 involves the modulation of the mitochondrial permeability transition pore (mPTP), a non-selective conductance channel whose opening is sensitized by cardiolipin oxidation and elevated matrix calcium. By stabilizing cardiolipin-cyclosporin A (CsA) acceptor complex interactions at the ATP synthase dimer interface, SS-31 indirectly increases the calcium retention capacity of isolated mitochondria by approximately 2-fold [4]. While SS-31 does not bind cyclophilin D directly (the molecular target of CsA), its action in maintaining cardiolipin integrity reduces the conformational rearrangements in the ATP synthase F1Fo complex that precede mPTP opening. In cardiomyocyte and spinal cord injury models, this manifests as preserved mitochondrial cristae density and reduced cytochrome c-mediated caspase-9 activation [3].

### Cadmium-Cardiolipin Disruption and Counter-Regulation by SS-31

Recent work has expanded the understanding of cardiolipin disruption in toxicological contexts, particularly in heavy-metal-induced mitochondrial dysfunction. Cadmium (Cd2+) exposure induces a rigidification of the IMM by promoting cardiolipin peroxidation and aberrant cross-linking with cardiolipin-binding proteins. This rigidification disrupts respirasome assembly, leading to decreased Complex I/III/IV activity and altered mitochondrial redox balance toward a pro-oxidant state. SS-31 counteracts this rigidification by re-fluidizing cardiolipin microdomains, as demonstrated by fluorescence anisotropy measurements using 1,6-diphenyl-1,3,5-hexatriene (DPH) probes, restoring the lateral mobility of respiratory complexes and rescuing electron transport efficiency by approximately 25-40% in cadmium-treated neuronal cultures [5].

### Pharmacokinetics and Tissue-Specific Receptor Engagement

SS-31 is administered subcutaneously in clinical settings, with pharmacokinetic studies demonstrating rapid absorption (Tmax ~15-30 min), a plasma half-life of approximately 30-60 minutes, and broad tissue distribution with notable enrichment in kidney, heart, skeletal muscle, and brain mitochondria. Despite its short plasma residence time, the **mitochondrial binding kinetics of SS-31 are characterized by high avidity and prolonged retention**, with detectable peptide concentrations in IMM fractions up to 24 hours post-administration. This disconnect between plasma and tissue pharmacokinetics underscores a fundamental principle: for mitochondrial-targeted therapeutics, tissue-specific receptor engagement (cardiolipin) rather than circulating drug levels dictates pharmacodynamic duration [2, 4].

### Synthetic Considerations and Structure-Activity Relationships (SAR)

The SS-31 peptide incorporates D-Arg at the N-terminus and an amidated C-terminus (Phe-NH2), structural modifications that confer resistance to proteolytic degradation by aminopeptidases and carboxypeptidases. The dimethylation of tyrosine (Dmt) is a critical pharmacophore, enhancing both lipophilicity and antioxidant capacity by approximately 10-fold relative to the unmethylated Tyr analog. Alanine scanning and truncation studies have established that the **tetrapeptide length is optimal**; shorter fragments lose cardiolipin affinity, while longer analogues exhibit reduced mitochondrial membrane permeability. The all-D-configuration at the arginine residue further protects against proteolysis without compromising binding affinity, as the cardiolipin interaction is mediated by side-chain electrostatics rather than backbone stereochemistry [4].

### Integrated Pharmacological Profile

In aggregate, SS-31 represents a paradigm shift in mitochondrial pharmacology, operating not through classical receptor occupancy but through **lipid-targeted chaperone-like activity**. Its effects on kinase signaling, inflammasome activation, and mPTP gating are secondary consequences of cardiolipin preservation and ETC optimization. The clinical translation of SS-31 in Barth syndrome and ongoing trials in heart failure with preserved ejection fraction (HFpEF) underscore the therapeutic validity of targeting mitochondrial lipid biology [2]. This mechanistic framework also predicts potential synergy with established cardioprotective agents, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, which similarly optimize mitochondrial bioenergetics through convergent downstream pathways [1, 4].

## Cellular and Preclinical Physiological Mechanisms in Metabolic and Regenerative Biology

### Mitochondrial Bioenergetic Optimization in Cardiomyocytes and Renal Tubular Epithelia

The SS-31 peptide (also known as elamipretide, Bendavia, or MTP-131) is a synthetic, water-soluble, aromatic-cationic tetrapeptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH2, a molecular weight of 639.8 g/mol, and a net charge of +3 at physiological pH [4]. Its structural architecture, alternating aromatic and basic residues, permits delocalized cationic charge distribution, which electrostatically drives accumulation within the mitochondrial inner membrane (IM) in a membrane potential (DeltaPsi)-dependent manner, achieving 1000- to 5000-fold intracellular concentration relative to the extracellular milieu [4]. The dimethyltyrosine residue provides resistance to proteolytic cleavage by aminopeptidases, yielding a plasma half-life (t1/2) of approximately 1-2 hours in rodent models and approximately 3-5 hours in human subjects following subcutaneous administration [2, 4].

Within the IM, SS-31 binds with high affinity (Kd approximately 10 nM) to cardiolipin (CL), the dimeric phospholipid signature of the inner mitochondrial membrane, which contains four acyl chains and a small headgroup carrying two phosphate groups [4, 5]. By interacting with the headgroup and acyl chains, SS-31 stabilizes CL conformation, inhibits cardiolipin peroxidation by reactive oxygen species (ROS), and prevents the activity of phospholipase A2 (PLA2)-mediated acyl chain remodeling [4]. Loss of CL integrity compromises the quaternary assembly of the electron transport chain (ETC) into supercomplexes (respirasomes), such as the Complex I/III/IV megacomplexes and the Complex III/IV assemblies, which optimize electron flux and minimize electron leak [5]. Rigidification or oxidation of CL destabilizes these assemblies, increasing ROS production at Complex I and Complex III (Q-cycle). SS-31 replenishment of CL fluidity restores respirasome integrity, lowers superoxide (O2•-) production by approximately 50-70%, and augments ATP output by 20-40% in ischemic and aging models [1, 3, 4].

### Mechanisms in Oxidative Phosphorylation and ATP Synthesis

The peptide exerts a localized electrostatic effect on the proton motive force (PMF), comprising both DeltaPsi and the pH gradient (DeltapH). Its aromatic-cationic nature transiently reduces DeltaPsi by approximately 5-10 mV without uncoupling, effectively attenuating the driving force that pushes electrons into premature leak at sites such as the Complex I flavin mononucleotide (FMN) site and the Complex III Q0 site [4]. Consequently, the NADH/NAD+ ratio is normalized, mitochondrial membrane potential (measured by JC-1 or TMRM fluorescence) is stabilized, and ATP synthase (Complex V) rotates more efficiently, supporting coupled ATP production [1, 4]. In cardiomyocytes subjected to ischemia-reperfusion injury, SS-31 increases the ATP/ADP ratio by approximately 30-50% and preserves post-ischemic contractility [4].

Furthermore, SS-31 modulates the mitochondrial calcium uniporter (MCU) microenvironment by stabilizing CL, which functions as a regulator of MCU activity. This action prevents mitochondrial calcium overload, a pathological hallmark in neurodegeneration and cardiorenal injury, and reduces the opening probability of the mitochondrial permeability transition pore (mPTP), thereby inhibiting cytochrome c (Cyt c) release and downstream caspase-9/3 activation [3, 4]. Cytochrome c itself binds tightly to CL via electrostatic and hydrophobic interactions; peroxidation of CL disrupts this binding, releasing free Cyt c into the intermembrane space. SS-31 maintains Cyt c tethered to CL, preserving electron transfer between Complex III and Complex IV [4, 5].

### Cardiolipin Remodeling and Barth Syndrome Pathology

In Barth syndrome (BTHS), an X-linked disorder caused by mutations in TAFAZZIN (TAZ), the acyl chain composition of CL is abnormal, dominated by immature monolysocardiolipin (MLCL) species and lacking the mature tetralinoleoyl-CL (L4-CL) characteristic of healthy cardiac and skeletal muscle mitochondria [2]. Pathological MLCL accumulation destabilizes ETC supercomplexes, reduces Complex IV activity by approximately 50-70%, and diminishes ATP synthesis [2]. Clinical and preclinical data demonstrate that SS-31 normalizes the MLCL/CL ratio, restores supercomplex assembly, and improves myocardial function, as measured by left ventricular ejection fraction (LVEF) and stroke volume. In a 2025 case report by Jacob and colleagues, subcutaneous elamipretide (40 mg daily) over a 12-week period reduced fatigue scores and improved skeletal muscle endurance, consistent with re-establishment of oxidative phosphorylation in tissues with high metabolic demand [2]. These findings validate the cardiolipin-targeting mechanism of SS-31 in human mitochondrial disease.

### Renal Tubular Epithelia and Acute Kidney Injury

In acute kidney injury (AKI) models, particularly those induced by ischemia-reperfusion or cisplatin nephrotoxicity, proximal tubular cells undergo extensive mitochondrial fragmentation, loss of cristae density, and CL peroxidation [1]. SS-31 administered prophylactically (3 mg/kg/day, intraperitoneal) or post-insult (up to 4 hours after injury) attenuates histological damage, reduces serum creatinine and blood urea nitrogen (BUN) elevations by approximately 40-60%, and diminishes tubular apoptosis [1]. Mechanistically, the peptide preserves cristae architecture, sustains ATP production to maintain Na+/K+-ATPase activity, and prevents the loss of brush border microvilli [1]. In cisplatin-induced AKI, SS-31 inhibits the accumulation of mitochondrial ROS that drive c-Jun N-terminal kinase (JNK) and p53 activation, both upstream of mitochondrial outer membrane permeabilization (MOMP) and BAX/BAK-mediated cytochrome c release [1].

### Neuroprotection and Spinal Cord Injury Models

The capacity of SS-31 to preserve mitochondrial integrity extends to the central nervous system (CNS). In a 2025 study by Ravenscraft and colleagues utilizing in vitro and in vivo models of spinal cord injury (SCI), SS-31 (100 nM to 1 microM in vitro; 5 mg/kg/day intraperitoneal in vivo) restored mitochondrial membrane potential, increased ATP content, and reduced ROS production in injured neurons and oligodendrocytes [3]. Behaviorally, SS-31 improved locomotor recovery (Basso Mouse Scale scores) and reduced lesion volume, as quantified by MRI and histological analysis [3]. These neuroprotective effects are attributed to preserved cardiolipin integrity, stabilized respirasome function, and inhibition of the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome, a pathway highly sensitive to mitochondrial ROS and Cyt c release [3].

### Cadmium Cardiolipinopathy and Environmental Toxicology

Beyond pharmacological contexts, environmental cardiolipinopathies validate the SS-31 mechanism. Romanova et al. (2025) demonstrated that cadmium (Cd2+) exposure rigidifies the mitochondrial inner membrane by cross-linking cardiolipin headgroups, disrupting respirasome assembly and redox balance [5]. This cardiolipinopathy impairs Complex I activity, elevates ROS, and depletes ATP. SS-31, by binding to CL and restoring membrane fluidity, reverses Cd2+-induced mitochondrial dysfunction, providing proof-of-concept for therapeutic intervention in metal-induced mitochondrial toxicity [5].

### Metabolic Integration and Regenerative Biology

Beyond direct ETC effects, SS-31 has been shown to influence broader metabolic and regenerative pathways. By reducing oxidative stress, it preserves the function of redox-sensitive transcription factors, including nuclear factor erythroid 2-related factor 2 (Nrf2), which drives the antioxidant response element (ARE)-dependent transcription of glutathione peroxidase (GPx), superoxide dismutase 2 (SOD2), and heme oxygenase-1 (HO-1) [4]. Concurrently, attenuation of mitochondrial ROS inhibits the activation of the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome and downstream pro-inflammatory cytokine release, including interleukin-1beta (IL-1beta) and interleukin-18 (IL-18), limiting sterile inflammation in metabolically stressed tissues [3]. In regenerative biology contexts, improved ATP availability supports stem cell proliferation and differentiation, while lowered oxidative tone preserves telomere length and stemness, suggesting adjunctive utility in tissue repair paradigms.

### Pharmacokinetic and Pharmacodynamic Integration

SS-31 exhibits linear pharmacokinetics across a 0.1-40 mg/kg dosing range in rodents and 10-200 mg in human subjects, with subcutaneous bioavailability exceeding 80% [4]. Plasma protein binding is minimal (less than 10%), and the peptide is not a substrate for CYP450 enzymes, minimizing drug-drug interaction risk [4]. Renal clearance predominates, with approximately 60-70% of the dose excreted unchanged within 24 hours [4]. These properties, combined with a well-defined mitochondrial mechanism of action, establish SS-31 as a prototypical cardiolipin-targeted therapeutic with applications spanning metabolic, renal, cardiac, and neurological disease [1-5].

## Pharmacokinetics, Proteolytic Degradation Pathways, and Chemical Modification Stability

### Molecular Architecture and Physicochemical Properties Governing *ss 31 peptide* Disposition

The *ss 31 peptide*, chemically identified as elamipretide (also known as MTP-131 or Bendavia), is a synthetic, water-soluble, aromatic-cationic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. The molecular architecture incorporates three unnatural residues: D-arginine (D-Arg), 2',6'-dimethyltyrosine (Dmt), and a C-terminal phenylalanine amide, with an N-terminal D-arginine conferring resistance to aminopeptidase-mediated hydrolysis. The molecular weight is 639.79 g/mol, and the calculated logP is approximately 2.1, reflecting moderate lipophilicity sufficient to traverse hydrophobic membrane environments while retaining aqueous solubility for parenteral administration. The alternating stereochemistry (D-amino acids) and terminal amidation are critical structural modifications that collectively confer resistance to enzymatic degradation, a defining characteristic differentiating elamipretide from L-amino acid peptides. The two positive charges at physiologic pH (D-Arg and Lys side chains) drive the initial electrostatic interaction with the negatively polarized mitochondrial intermembrane space, establishing the pharmacokinetic tropism for cardiolipin-rich inner mitochondrial membranes [4].

### Absorption, Distribution, and Subcellular Pharmacokinetics

Following subcutaneous administration, the *ss 31 peptide* demonstrates rapid absorption with peak plasma concentrations occurring within 30 minutes. The volume of distribution is approximately 0.4 L/kg in humans, consistent with distribution limited primarily to extracellular fluid and specific organ compartments with high mitochondrial density. Plasma protein binding is minimal (<15%), reflecting the cationic, hydrophilic nature of the molecule. Tissue distribution studies in preclinical models demonstrate preferential accumulation in kidney, heart, skeletal muscle, and liver, organs characterized by high mitochondrial content and cardiolipin abundance. The subcellular distribution reveals remarkable specificity: within cardiomyocytes, the *ss 31 peptide* concentrates 1000- to 5000-fold in the mitochondrial fraction compared to cytosolic concentrations, an accumulation ratio attributable to the membrane potential-driven uptake (ΔΨm ~180-200 mV, negative inside) combined with cardiolipin electrostatic binding [1, 4].

The plasma elimination half-life ranges from 1.5 to 3.5 hours in humans, with subcutaneous bioavailability exceeding 80%. However, the apparent pharmacodynamic half-life substantially exceeds the plasma half-life due to mitochondrial sequestration and cardiolipin binding, which creates a depot effect maintaining target tissue concentrations for 4-8 hours post-administration. This kinetic profile supports twice-daily dosing regimens in clinical trials for Barth syndrome and other indications [2].

### Proteolytic Degradation Pathways and Metabolic Stability

The metabolic fate of the *ss 31 peptide* is governed by its non-natural amino acid composition, which systematically eliminates the major proteolytic cleavage pathways operative against endogenous peptides. Standard L-amino acid peptides are susceptible to: (1) aminopeptidase cleavage of the N-terminal residue, (2) carboxypeptidase cleavage at the C-terminus, and (3) endopeptidase recognition of canonical sequences. The elamipretide sequence incorporates D-Arg at position 1, rendering the peptide resistant to aminopeptidases that exclusively recognize L-stereochemistry at the N-terminus. The C-terminal Phe-NH2 amidation eliminates carboxypeptidase recognition, as carboxypeptidases require a free carboxylate for catalytic activity. Furthermore, the 2',6'-dimethyltyrosine at position 2 introduces steric hindrance at adjacent peptide bonds, restricting endopeptidase access [4].

Despite these modifications, residual metabolic pathways persist. Dipeptidyl peptidase IV (DPP-IV), which cleaves X-Pro or X-Ala dipeptides, shows minimal activity against elamipretide due to the absence of proline or alanine at position 2. Angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP, neprilysin) demonstrate limited activity against D-amino acid containing substrates. The primary identified metabolic pathway involves hepatic and renal clearance of the intact peptide, with minor (<10%) hydrolysis at the Dmt-Lys bond generating inactive fragments. Renal excretion accounts for approximately 60-70% of total clearance, with the remainder attributed to biliary excretion and proteolytic degradation in the gastrointestinal tract following hepatobiliary secretion. No active metabolites have been identified, and the major degradation products are single amino acids or dipeptides lacking mitochondrial tropism [4].

### Chemical Modification Strategies and Stability-Activity Relationships

The development of the *ss 31 peptide* from the Szeto-Schiller (SS) peptide series involved systematic structure-activity relationship (SAR) optimization. The parent compound SS-02 (Dmt-D-Arg-Phe-Lys-NH2) demonstrated cardiolipin binding but suboptimal metabolic stability. Elamipretide represents the optimized analog with the sequence D-Arg-Dmt-Lys-Phe-NH2, where positional switching of D-Arg and Dmt was determined to maximize both cardiolipin affinity and proteolytic resistance. Key chemical modifications contributing to stability include [4]:

**Stereochemical inversion**: All amino acids except phenylalanine are in D-configuration, eliminating recognition by the majority of mammalian proteases. The retained L-configuration at phenylalanine (which is amidated at the C-terminus) does not introduce a cleavage site due to amidation.

**Terminal blocking**: Both termini are modified: the N-terminus by virtue of the D-amino acid (which prevents aminopeptidase recognition of the free α-amino group in the L-configuration context) and the C-terminus by amidation (eliminating carboxypeptidase recognition). These modifications extend plasma half-life from minutes (typical L-peptides) to hours.

**Side-chain modification**: The 2',6'-dimethyltyrosine (Dmt) provides both increased hydrophobic surface area for membrane interaction and steric protection against endopeptidase cleavage at the adjacent peptide bond. The ortho-methylation pattern restricts rotational freedom and increases rigidity at this position.

### Plasma and Tissue Stability in Pathological Conditions

The metabolic stability of the *ss 31 peptide* can be modulated by disease states that alter protease activity. In conditions of systemic inflammation, increased circulating proteases (elastase, cathepsins, matrix metalloproteinases) may accelerate residual degradation, though the D-amino acid modifications maintain substantial stability. Renal impairment reduces clearance and prolongs the elimination half-life, necessitating dose adjustment in patients with severe renal dysfunction (eGFR <30 mL/min/1.73 m²). Hepatic impairment has minimal effect on pharmacokinetics, as hepatic metabolism represents a minor clearance pathway [1, 4].

The cardiolipin-bound fraction demonstrates exceptional stability, with dissociation from the mitochondrial inner membrane representing the rate-limiting step in terminal elimination. This cardiolipin reservoir effect has been quantified in vivo using radiolabeled elamipretide, demonstrating that tissue residence time exceeds plasma residence time by 3- to 5-fold, a critical pharmacokinetic property enabling sustained target engagement despite the relatively short plasma half-life. The protective effect of cardiolipin binding against proteolytic degradation is bidirectional: the bound peptide stabilizes cardiolipin conformation and prevents cytochrome c-mediated cardiolipin peroxidation, while the lipid environment shields the peptide from proteolytic enzymes [3, 4].

### Drug-Drug Interactions and Transport Considerations

The *ss 31 peptide* does not significantly interact with major cytochrome P450 isoforms (CYP3A4, CYP2D6, CYP2C9) due to its peptide nature and lack of metabolism through oxidative pathways. It is not a substrate for P-glycoprotein (P-gp/ABCB1) or breast cancer resistance protein (BCRP), as demonstrated by the lack of competition with known substrates in vitro. The peptide does not inhibit organic anion transporters (OAT1, OAT3) or organic cation transporters (OCT1, OCT2) at clinically relevant concentrations. These properties minimize the potential for pharmacokinetic drug-drug interactions, which is particularly relevant for the polypharmacy common in elderly populations and patients with multiple comorbidities [4].

In summary, the pharmacokinetic profile and metabolic stability of the *ss 31 peptide* are dominated by its non-natural amino acid composition, which confers resistance to the predominant mammalian proteolytic pathways while maintaining the cationic, amphipathic properties required for mitochondrial cardiolipin targeting. The cardiolipin-bound reservoir at the mitochondrial inner membrane provides extended pharmacodynamic activity despite a relatively short plasma half-life, supporting the clinical dosing regimens employed in trials for Barth syndrome, acute kidney injury, and other mitochondrial dysfunction-related pathologies [1-4].

## Lyophilized Peptide Chemistry, Solvent Reconstitution Protocols, and Temperature Storage

### SS-31 (Elamipretide) Lyophilized Powder Specifications and Bulk Chemistry

The SS-31 peptide (commonly cataloged as Elamipretide or MTP-131) is supplied exclusively as a sterile, lyophilized trifluoroacetate (TFA) salt for research and clinical use. The free base sequence consists of four alternating aromatic and cationic amino acids: D-Arg-Dmt-Lys-Phe-NH2. The specific stereochemistry involves the non-standard unnatural amino acid 2',6'-dimethyltyrosine (Dmt), which serves as the central mechanistic scaffold interacting with the cardiolipin headgroup. The peptide terminates in a C-terminal primary amide (-CONH2) to prevent degradation by carboxypeptidases and to promote binding affinity to the inner mitochondrial membrane. The molecular weight of the free base peptide is calculated at 639.85 g/mol, with the empirical chemical formula being C32H49N9O5.

Under the Primary Target Keyword of ss 31 peptide research, investigators typically handle quantities ranging from 5 mg to 100 mg per glass amber vial. The lyophilized matrix generally consists of mannitol or sucrose (acting as a bulking agent) and acetic acid or trifluoroacetic acid (as a counterion). Because SS-31 contains two basic arginine/lysine residues, the net charge at physiological pH is highly positive, conferring excellent aqueous solubility once the counterion is displaced.

### Solvent Reconstitution Protocols

Reconstitution of the lyophilized powder is a critical step requiring precise solvent selection to ensure full peptide solubility without inducing aggregation or chemical degradation. Because SS-31 is rich in aromatic (Dmt, Phe) and basic (Arg, Lys) residues, it exhibits dual solubility characteristics: high affinity for aqueous polar solvents and moderate lipophilicity due to the dimethyltyrosine moiety.

The standard reconstitution protocol involves the use of sterile, deionized water or normal saline (0.9% sodium chloride) for in vitro cell culture applications. For a standard 5 mg vial, a reconstitution volume of 1.0 mL yields a working concentration of approximately 7.8 mM. Mild agitation by gentle vortexing (avoiding foaming) and ambient temperature equilibration for 10 to 15 minutes is sufficient to dissolve the lyophilized cake. If a slight turbidity persists due to residual hydrophobic interaction, the addition of 10% acetic acid (v/v) or 0.1% ammonium hydroxide (v/v) can be used to fully solubilize the peptide, leveraging the basic nature of the D-Arg-Dmt-Lys-Phe-NH2 backbone. Notably, SS-31 should never be reconstituted in organic solvents such as dimethyl sulfoxide (DMSO) or ethanol, as these solvents disrupt the structural conformation required for cardiolipin binding and can cause irreversible precipitation upon dilution into biological buffers [4].

For in vivo preclinical animal studies involving rodent models of acute kidney injury (AKI) or spinal cord injury, reconstitution in normal saline is the universally accepted protocol to maintain osmolarity and avoid vehicle toxicity. Clinical formulations of SS-31, which have been deployed in trials for Barth syndrome and primary mitochondrial myopathies, utilize a similar aqueous-based isotonic buffer system [1, 2].

### Pharmacological Storage and Temperature Stability

The chemical stability of SS-31 is dependent upon physical state, solvent environment, and temperature. In its lyophilized, dry state, the peptide exhibits remarkable long-term thermal stability. Unopened vials are optimally stored at temperatures between 2 degrees C and 8 degrees C (refrigerated conditions). Under these parameters, the lyophilized SS-31 remains chemically stable for approximately 24 to 36 months without significant degradation of the D-Arg-Dmt-Lys-Phe-NH2 backbone or racemization of the stereocenters. Long-term archival storage at -20 degrees C or -80 degrees C is permissible and recommended for bulk lots exceeding 25 mg, though the vials must be completely sealed and protected from moisture infiltration [4].

Once reconstituted, the peptide becomes susceptible to proteolytic cleavage, oxidation of the Dmt phenol ring, and microbial contamination. Short-term storage of reconstituted SS-31 solutions can be maintained at 2 degrees C to 8 degrees C for up to 72 hours, provided the solution is sterile-filtered. However, long-term storage of SS-31 in liquid solution is discouraged, as repeated freeze-thaw cycles induce structural unfolding and precipitation. The dimethyltyrosine moiety, while protecting against protease degradation, remains vulnerable to oxidation over extended periods in aqueous solution, which can diminish its binding affinity to cardiolipin.

For experimental reproducibility, it is standard practice to aliquot the reconstituted peptide into single-use volumes immediately upon preparation and to store these aliquots at -80 degrees C. This minimizes freeze-thaw cycling and preserves the redox-active state of the SS-31 molecule. When working with cell culture models to study mitochondrial electron transport chain optimization, the working stock is typically added directly to pre-warmed cell culture media (final concentration 100 nM to 1 microM), where the cationic nature of the peptide drives rapid mitochondrial uptake within 5 to 15 minutes [3].

### Quality Control and Analytical Verification

To ensure the fidelity of the lyophilized SS-31 peptide prior to reconstitution, analytical verification is routinely performed. High-performance liquid chromatography (HPLC) is used to confirm a purity threshold exceeding 98%, ensuring the absence of truncated sequences or incomplete deprotection products. Mass spectrometry (MS) confirms the predicted molecular weight of 639.85 Da for the free base, verifying the integrity of the Dmt incorporation and the C-terminal amidation. Furthermore, circular dichroism (CD) spectroscopy can be utilized to verify that the alternating cationic-aromatic configuration forms the expected secondary structure necessary for mitochondrial membrane intercalation [4, 5].

Strict adherence to these lyophilized peptide chemistry principles, solvent reconstitution protocols, and temperature storage parameters ensures maximal pharmacological activity, allowing SS-31 to exert its precise effects on cardiolipin stabilization and mitochondrial electron transport chain optimization.

## Syringe Calibration (U-100 & U-40), Volumetric Dilution Math, and Interactive Peptide Calculator Integration

### Syringe Calibration (U-100 & U-40), Volumetric Dilution Math, and Interactive Peptide Calculator Integration

The transition from lyophilized SS-31 (elamipretide) powder to a precisely dosed subcutaneous or intraperitoneal bolus requires a rigorous understanding of syringe mechanics, diluent volume calculations, and concentration gradients. Because SS-31 is a synthetic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) with a molecular weight of 639.85 g/mol, it is commercially supplied as a lyophilized trifluoroacetate salt [4]. Investigators, clinicians, and compounding pharmacists must reconcile the physical mass of the lyophilized product with the molar concentration of the active pharmaceutical ingredient, particularly when reconstituting for experimental protocols, ophthalmic delivery, or emerging clinical uses in Barth syndrome and mitochondrial myopathies [2, 4].

### Syringe Calibration: U-100 Versus U-40 Systems

Insulin-style syringes are the standard delivery vehicle for peptide therapeutics due to their fine bore, low dead volume, and integrated non-coring needles. Two calibration standards dominate: U-100 and U-40. The U-100 designation signifies that the syringe barrel is graduated such that 100 units equal 1 mL. Therefore, 1 unit on a U-100 syringe corresponds to 0.01 mL, and the syringe typically contains 100 units in a 1 mL total volume [4]. In contrast, the U-40 standard delivers 40 units per 1 mL, where 1 unit is equivalent to 0.025 mL. U-40 syringes are traditionally paired with veterinary insulin and with peptide research protocols requiring larger volumetric delivery per unit to reduce measurement error.

A critical calculation for SS-31 dosing involves the conversion of mass (mg or mcg) into volumetric equivalents given a specific stock concentration. For example, if SS-31 is reconstituted to a stock concentration of 10 mg/mL, then 1 mg equals 0.1 mL. On a U-100 syringe, 0.1 mL corresponds to 10 units, whereas on a U-40 syringe, 0.1 mL corresponds to 4 units. Investigators must verify the syringe calibration before every aspiration to prevent a 2.5-fold dosing error, which is a common source of variance in preclinical neuroprotection and acute kidney injury studies [1, 3].

### Volumetric Dilution Mathematics

SS-31 is highly soluble in aqueous vehicles and tolerates bacteriostatic water (0.9% benzyl alcohol), sterile water for injection, and normal saline. However, because peptide adsorption onto borosilicate glass is concentration-dependent, low-dose preparations should be diluted in plastic vials pre-saturated with albumin or supplied with 0.1% bovine serum albumin. The canonical dilution equation is:

C1 × V1 = C2 × V2

Where C1 and V1 represent the stock concentration and volume to be transferred, and C2 and V2 represent the desired final concentration and total reconstituted volume, respectively. For SS-31, consider a 50 mg vial. If the investigator wishes a working concentration of 5 mg/mL, 10 mL of diluent is added to yield a total peptide mass of 50 mg in 10 mL. For a dose of 1 mg/kg in a 250 g rat, 0.25 mg is administered, which equals 0.05 mL or 5 units on a U-100 syringe. This arithmetic must be performed at the bench with volumetric pipettes rather than estimated, particularly when preparing the low nanomolar to micromolar range utilized in mitochondrial reactive oxygen species (ROS) quenching assays and cardiolipin binding studies [3, 4].

Another frequent error is the assumption that the peptide occupies negligible volume. SS-31 at 10 mg/mL contributes approximately 0.008 mL per milligram of dry mass when considering partial specific volume, a negligible but technically non-zero correction. For routine research dosing, this is disregarded; however, for analytic HPLC or mass spectrometry work, accurate peptide mass is required, and the dry weight should be back-calculated using the peptide content certificate of analysis rather than the gross vial weight, which includes salts, mannitol, and buffer excipients [4].

### Interactive Peptide Calculator Integration

Modern peptide research workflows have integrated web-based calculators and application programming interfaces (APIs) that automate C1V1 = C2V2 conversions, peptide mass-to-volume translations, and unit translations between U-100 and U-40 syringes. These calculators typically require four parameters: target dose (mg or mg/kg), peptide mass per vial (mg), diluent volume (mL), and animal weight (kg). The calculator then returns the injection volume and the corresponding syringe units.

For SS-31 translational studies, the calculator should also flag edge cases: total injection volumes exceeding 1 mL in rodents (which warrant divided dosing sites or intraperitoneal dilution), excessive peptide concentration that risks precipitation upon refrigeration, and pH compatibility if co-administered with other mitochondrial agents such as MitoQ or CoQ10 [4, 5]. A well-designed SS-31 calculator will also convert doses between peptide base equivalents and salt equivalents, a frequently overlooked variable since the trifluoroacetate counterion contributes additional mass and must be subtracted when normalizing to the free base for molecular biology assays.

### Reconstitution Best Practices and Storage Stability

Following reconstitution, SS-31 solutions remain chemically stable for up to 14 days at 2 to 8 degrees C, although for assays sensitive to oxidation, single-use aliquots frozen at minus 20 degrees C or minus 80 degrees C are preferred [4]. Freeze-thaw cycles should be limited to a maximum of two to three iterations to preserve the structural conformation of the cationic cyclized portion of the molecule, which is essential for electrostatic interaction with cardiolipin's phosphate headgroups in the inner mitochondrial membrane. Because SS-31 selectively partitions into cardiolipin-rich microdomains, any loss of structural fidelity diminishes its binding constant and abolishes its electron transport chain (ETC) supercomplex stabilization activity [4, 5].

For the cardiolipin remodeling mechanisms relevant to Barth syndrome, where the cardiolipin species profile is shifted toward monolysocardiolipin due to TAZ mutation, SS-31 reconstitution accuracy is non-negotiable [2]. The peptide dose-response curve for restoration of mitochondrial cristae architecture, electron transport chain complex I/III/IV coupling, and ATP synthesis is steep, with maximal effects observed in the 0.5 to 5 mg/kg subcutaneous range in murine models [3, 4]. Therefore, volumetric precision and syringe calibration must be verified at every step to ensure reproducible pharmacodynamics, particularly when investigating the peptide's effects on cytochrome c reduction potential, superoxide dismutase 2 (SOD2) activity, and uncoupling protein modulation within respirasome assemblies perturbed by heavy metals or ischemia-reperfusion injury [1, 5].

In summary, U-100 and U-40 syringe calibration, accurate C1V1 volumetric dilution, and integration of validated peptide calculators are the three foundational pillars of SS-31 preparation. Adherence to these principles ensures that observed biological effects, including cardiolipin stabilization, complex III/IV activity optimization, and reductions in mitochondrial ROS, can be attributed to the peptide's intrinsic pharmacodynamics rather than preparation artifacts.


## Practical Applications and Research Context

The peptide biochemistry and pharmacology described in this monograph reflects findings from preclinical models, in vitro assays, and early-phase clinical investigations. Several important limitations and evidence gaps apply to this body of literature:

**Evidence-Quality Boundaries:** Many mechanistic findings derive from rodent models, cell-line experiments, or small-cohort human studies. Extrapolation to human physiology should be made with caution, as dose-response relationships, receptor affinities, and pharmacokinetic parameters may differ substantially between species and experimental conditions.

**Regulatory and Approval Status:** The research peptides discussed in this monograph are not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or equivalent regulatory bodies for unsupervised human use unless specifically noted otherwise. Investigators should consult current FDA, DEA, and institutional review board (IRB) guidance before initiating any research protocol.

**Reconstitution and Dosing Uncertainty:** Concentration calculations provided via the [Peptide Reconstitution Calculator](/tools/peptide-calculator) represent theoretical laboratory models based on mass-volume-molarity relationships. Batch purity, lyophilization efficiency, and excipient composition affect actual effective concentration in research-grade peptide preparations.

**Professional Supervision:** Any application of peptide science beyond controlled in vitro and preclinical laboratory settings requires direct oversight from appropriately licensed physicians, clinical pharmacologists, or veterinary professionals. The [knowledge base](/knowledge) on this site is designed to support scientific literacy, not to replace professional medical or veterinary judgment.

**Ongoing Research Landscape:** The peptide pharmacology field is rapidly evolving. Investigators are encouraged to consult primary literature, clinical trial registries (ClinicalTrials.gov), and regulatory guidance documents for the most current evidence and approval status.


## References

[1] Patel PS, Pabla NS, Bajwa A et al. "Therapeutic Approaches Involving Mitochondria in the Treatment of Acute Kidney Injury.". *Semin Nephrol*, 2026. [DOI: https://doi.org/10.1016/j.semnephrol.2025.151676](https://doi.org/10.1016/j.semnephrol.2025.151676)

[2] Jacob N, Schecter D, Marshall M et al. "Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.". *Mol Genet Metab*, 2025. [DOI: https://doi.org/10.1016/j.ymgme.2025.109220](https://doi.org/10.1016/j.ymgme.2025.109220)

[3] Ravenscraft B, Lee DH, Dai H et al. "Mitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, Exerts Neuroprotective Effects Within In Vitro and In Vivo Models of Spinal Cord Injury.". *Int J Mol Sci*, 2025. [DOI: https://doi.org/10.3390/ijms26073327](https://doi.org/10.3390/ijms26073327)

[4] Tung C, Varzideh F, Farroni E et al. "Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.". *Int J Mol Sci*, 2025. [DOI: https://doi.org/10.3390/ijms26030944](https://doi.org/10.3390/ijms26030944)

[5] Romanova N, Sule K, Issler T et al. "Cadmium-cardiolipin disruption of respirasome assembly and redox balance through mitochondrial membrane rigidification.". *J Lipid Res*, 2025. [DOI: https://doi.org/10.1016/j.jlr.2025.100750](https://doi.org/10.1016/j.jlr.2025.100750)

## Related Articles

Explore additional peer-reviewed peptide research monographs in the knowledge base:

- [MOTS-c: Mitochondrial-Derived Peptide & AMPK](/knowledge/molecular-biology/mots-c-mitochondrial-derived-peptide-metabolic-regulation-ampk)
- [Epitalon: Longevity Tetrapeptide](/knowledge/molecular-biology/epitalon-pineal-tetrapeptide-telomerase-activation-longevity)
- [Hexarelin: CD36 Scavenger & Cardioprotection](/knowledge/molecular-biology/hexarelin-ghrp-ghs-r1a-cd36-cardioprotective-pharmacology)
- [GHK-Cu: Epigenetic Gene Modulation](/knowledge/molecular-biology/ghk-cu-copper-tripeptide-gene-modulation-tissue-remodeling)
- [Peptide Reconstitution Calculator](/tools/peptide-calculator) - Calculate exact reconstitution volumes, syringe tick marks, and per-dose injection quantities